Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2012

Open Access 01-04-2012 | Research article

Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells

Authors: Laura Abalsamo, Francesca Spadaro, Giuseppina Bozzuto, Luisa Paris, Serena Cecchetti, Luana Lugini, Egidio Iorio, Agnese Molinari, Carlo Ramoni, Franca Podo

Published in: Breast Cancer Research | Issue 2/2012

Login to get access

Abstract

Introduction

Acquisition of mesenchymal characteristics confers to breast cancer (BC) cells the capability of invading tissues different from primary tumor site, allowing cell migration and metastasis. Regulators of the mesenchymal-epithelial transition (MET) may represent targets for anticancer agents. Accruing evidence supports functional implications of choline phospholipid metabolism in oncogene-activated cell signaling and differentiation. We investigated the effects of D609, a xanthate inhibiting phosphatidylcholine-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS), as a candidate regulator of cell differentiation and MET in the highly metastatic BC cell line MDA-MB-231.

Methods

PC-PLC expression and activity were investigated using confocal laser scanning microscopy (CLSM), immunoblotting and enzymatic assay on human MDA-MB-231 compared with MCF-7 and SKBr3 BC cells and a nontumoral immortalized counterpart (MCF-10A). The effects of D609 on PC-PLC and SMS activity, loss of mesenchymal markers and changes in migration and invasion potential were monitored in MDA-MB-231 cells by enzymatic assays, CLSM, immunoblotting and transwell chamber invasion combined with scanning electron microscopy examinations. Cell proliferation, formation and composition of lipid bodies and cell morphology were investigated in D609-treated BC cells by cell count, CLSM, flow-cytometry of BODIPY-stained cells, nuclear magnetic resonance and thin-layer chromatography.

Results

PC-PLC (but not phospholipase D) showed 2- to 6-fold activation in BC compared with nontumoral cells, the highest activity (up to 0.4 pmol/μg protein/min) being detected in the poorly-differentiated MDA-MB-231 cells. Exposure of the latter cells to D609 (50 μg/mL, 24-72 h) resulted into 60-80% PC-PLC inhibition, while SMS was transiently inhibited by a maximum of 21%. These features were associated with progressive decreases of mesenchymal traits such as vimentin and N-cadherin expression, reduced galectin-3 and milk fat globule EGF-factor 8 levels, β-casein formation and decreased in vitro cell migration and invasion. Moreover, proliferation arrest, changes in cell morphology and formation of cytosolic lipid bodies typical of cell differentiation were induced by D609 in all investigated BC cells.

Conclusions

These results support a critical involvement of PC-PLC in controlling molecular pathways responsible for maintaining a mesenchymal-like phenotype in metastatic BC cells and suggests PC-PLC deactivation as a means to promote BC cell differentiation and possibly enhance the effectiveness of antitumor treatments.
Appendix
Available only for authorised users
Literature
1.
Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010, 15: 117-134. 10.1007/s10911-010-9178-9.CrossRefPubMedPubMedCentral
2.
Podo F: Tumour phospholipid metabolism. NMR Biomed. 1999, 12: 413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U.CrossRefPubMed
3.
4.
Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM: Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev. 2010, 110: 3043-3059. 10.1021/cr9004007.CrossRefPubMedPubMedCentral
5.
Janardhan S, Srivani P, Sastry GN: Choline kinase: an important target for cancer. Curr Med Chem. 2006, 13: 1169-1186. 10.2174/092986706776360923.CrossRefPubMed
6.
Podo F, Canevari S, Canese R, Ricci A, Pisanu ME, Iorio E: MR evaluation of response to targeted treatment in cancer cells. NMR Biomed. 2011, 24: 648-672.PubMed
7.
Beloueche-Babari M, Workman P, Leach MO: Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents. Cell Cycle. 2011, 10: 2883-2893. 10.4161/cc.10.17.17192.CrossRefPubMed
8.
Glunde K, Bhujwalla ZM, Ronen SM: Choline metabolism in malignant transformation. Nature Rev Cancer. 2011, 11: 835-848.
9.
Eliyahu G, Kreizman T, Degani H: Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007, 120: 1721-1730. 10.1002/ijc.22293.CrossRefPubMed
10.
Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65: 9369-7936. 10.1158/0008-5472.CAN-05-1146.CrossRefPubMed
11.
Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F: Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010, 70: 2126-2135. 10.1158/0008-5472.CAN-09-3833.CrossRefPubMedPubMedCentral
12.
Glunde K, Raman V, Mori N, Bhujwalla ZM: RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005, 65: 11034-11043. 10.1158/0008-5472.CAN-05-1807.CrossRefPubMed
13.
Ramoni C, Spadaro F, Barletta B, Dupuis ML, Podo F: Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res. 2004, 299: 370-382. 10.1016/j.yexcr.2004.05.037.CrossRefPubMed
14.
Liu X, Zhao Q, Araki S, Zhang S, Miao J: Contrasting effects of phosphatidylinositol- and phosphatidylcholine-specific phospholipases C on apoptosis in cultured endothelial cells. Endothelium. 2006, 13: 205-211. 10.1080/10623320600760423.CrossRefPubMed
15.
Ramoni C, Spadaro F, Menegon M, Podo F: Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells. J Immunol. 2001, 167: 2642-2650.CrossRefPubMed
16.
Spadaro F, Cecchetti S, Sanchez M, Ausiello CM, Podo F, Ramoni C: Expression and role of phosphatidylcholine-specific phospholipase C in human NK and T lymphocyte subsets. Eur J Immunol. 2006, 36: 3277-3287. 10.1002/eji.200635927.CrossRefPubMed
17.
Cecchetti S, Spadaro F, Lugini L, Podo F, Ramoni C: Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur J Immunol. 2007, 37: 2912-2922. 10.1002/eji.200737266.CrossRefPubMed
18.
Fantuzzi L, Spadaro F, Purificato C, Cecchetti S, Podo F, Belardelli F, Gessani S, Ramoni C: Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages. Blood. 2008, 111: 3355-3363. 10.1182/blood-2007-08-104901.CrossRefPubMedPubMedCentral
19.
Wang N, Sun C, Huo S, Zhang Y, Zhao J, Zhang S, Miao J: Cooperation of phosphatidylcholine-specific phospholipase C and basic fibroblast growth factor in the neural differentiation of mesenchymal stem cells in vitro. Int J Biochem Cell Biol. 2008, 40: 294-306. 10.1016/j.biocel.2007.08.003.CrossRefPubMed
20.
Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F: Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res. 2008, 68: 6541-6549. 10.1158/0008-5472.CAN-07-6763.CrossRefPubMed
21.
Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F: Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010, 12: R27-10.1186/bcr2575.CrossRefPubMedPubMedCentral
22.
Amtmann E: The antiviral, antitumoral xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drug Exp Clin Res. 1996, 22: 287-294.
23.
Chan SYV, Hilchie AL, Brown MG, Anderson R, Hoskin DW: Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species. Exp Mol Pathol. 2007, 82: 1-11. 10.1016/j.yexmp.2006.03.001.CrossRefPubMed
24.
Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S: Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res. 1996, 16: 1399-1412.PubMed
25.
Clark MA, Shorr RG, Bomalaski JS: Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phospholipase C in mammalian cells. Biochem Biophys Res Commun. 1986, 140: 114-119. 10.1016/0006-291X(86)91065-X.CrossRefPubMed
26.
Meng A, Luberto C, Meier P, Bai A, Yang X, Hannun YA, Zhou D: Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp Cell Res. 2004, 292: 385-392. 10.1016/j.yexcr.2003.10.001.CrossRefPubMed
27.
Iorio E, Di Vito M, Spadaro F, Ramoni C, Lococo E, Carnevale R, Lenti L, Strom R, Podo F: Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. Biochim Biophys Acta. 2003, 1634: 1-14.CrossRefPubMed
28.
Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 1957, 226: 497-509.PubMed
29.
Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47: 3239-3245.PubMed
30.
Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caragia M, Budillon A, Meo G, Arancia G, Molinari A: The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?. J Invest Dermatol. 2008, 128: 957-971. 10.1038/sj.jid.5701082.CrossRefPubMed
31.
Mateos MV, Salvador GA, Giusto NM: Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings. Biochim Biophys Acta. 2010, 1798: 624-636. 10.1016/j.bbamem.2009.12.008.CrossRefPubMed
32.
Drabsch Y, Ramsay RG, Gonda TJ: MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010, 12: R55-10.1186/bcr2614.CrossRefPubMedPubMedCentral
33.
Gocze PM, Freeman DA: Factors underlying the variability of lipid droplet fluorescence in MA-10 Leydig tumor cells. Cytometry. 1994, 17: 151-158. 10.1002/cyto.990170207.CrossRefPubMed
34.
Münster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001, 61: 2945-2952.PubMed
35.
Kokkinos MI, Wong MK, Newgreen DF, Thompson EW, Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs. 2007, 185: 191-203. 10.1159/000101320.CrossRefPubMed
36.
Honjo Y, Nangia-Makker P, Inohara H, Raz A: Downregulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res. 2001, 7: 661-668.PubMed
37.
Markowska AI, Liu FT, Panjvani N: Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med. 2010, 207: 1981-1993. 10.1084/jem.20090121.CrossRefPubMedPubMedCentral
38.
Neutzner M, Lopez T, Feng X, Bergmann-Leitner ES, Leitner WW, Udey MC: MFG-E8/lactadherin promotes tumor growth in an angiogenesis-dependent transgenic mouse model of multistage carcinogenesis. Cancer Res. 2007, 67: 6777-6785. 10.1158/0008-5472.CAN-07-0165.CrossRefPubMed
39.
Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswaran S, Chen L, Anderson KS, Ellisen LW, Sgroi D, Schmidt EV: The integrin αvβ3-5 ligand MFG-E8 is a p63/p73 target gene in triple negative breast cancers but exhibits suppressive functions in ER+ and erbB2+ breast cancers. Cancer Res. 2011, 71: 937-945. 10.1158/0008-5472.CAN-10-1471.CrossRefPubMed
40.
Charras G, Paluch E: Blebs lead the way: how to migrate without lamellipodia. NatRev Mol Cell Biol. 2008, 9: 730-736.CrossRef
41.
Singh ATK, Radeff JM, Kunnel JG, Stern PH: Phosphatidylcholine-specific phospholipase C inhibitor, tricyclodecan-9-yl xanthogenate (D609), increases phospholipase D-mediated phosphatidylcholine hydrolysis in UMR-106 osteoblastic osteosarcoma cells. Biochim Biophys Acta. 2000, 1487: 201-208.CrossRefPubMed
42.
Kang Y, Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004, 118: 277-279. 10.1016/j.cell.2004.07.011.CrossRefPubMed
43.
Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005, 24: 7443-7454. 10.1038/sj.onc.1209091.CrossRefPubMed
44.
Yan W, Cao QJ, Arenas RB, Bentley B, Shao R: GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 2010, 285: 14042-14051. 10.1074/jbc.M110.105262.CrossRefPubMedPubMedCentral
45.
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbel LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral
46.
Glinsky VV, Kiriakova G, Glinskii OV, Mossine VV, Mawhinney TP, Turk JR, Glinskii AB, Huxley VH, Price JE, Glinsky GV: Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia. 2009, 11: 901-909.CrossRefPubMedPubMedCentral
47.
Guarino M, Rubino B, Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007, 39: 305-318. 10.1080/00313020701329914.CrossRefPubMed
48.
Zhou H, Huang S: mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr. 2010, 10: 1-16.CrossRef
49.
Platet N, Prévostel C, Derocq D, Joubert D, Rochefort H, Garcia M: Breast cancer cell invasiveness: correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and -negative cells. Int J Cancer. 1998, 75: 750-756. 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A.CrossRefPubMed
50.
Beloueche-Babari M, Peak JC, Jackson LE, Tiet MY, Leach MO, Eccles SA: Changes in choline metabolism as potential biomarkers of phospholipase Cγ-1 inhibition in human prostate cancer cells. Mol Cancer Ther. 2009, 8: 1305-1311. 10.1158/1535-7163.MCT-09-0039.CrossRefPubMed
51.
Rizzo MA, Shome K, Watkins SC, Romero G: The recruitment of raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. J Biol Chem. 2000, 275: 23911-23918. 10.1074/jbc.M001553200.CrossRefPubMed
52.
Zhao C, Du G, Skowronek K, Frohamn MA, Bar-Sagi D: Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by SoS. Nat Cell Biol. 2007, 9: 706-712.PubMed
53.
Mérida I, Avila-Flores A, Garcia J, Merino E, Almena M, Torres-Ayuso P: Diacylglycerol kinase alpha, from negative modulation of T cell activation to control of cancer progression. Adv Enzyme Regul. 2009, 49: 174-188. 10.1016/j.advenzreg.2009.01.003.CrossRefPubMed
Metadata
Title
Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells
Authors
Laura Abalsamo
Francesca Spadaro
Giuseppina Bozzuto
Luisa Paris
Serena Cecchetti
Luana Lugini
Egidio Iorio
Agnese Molinari
Carlo Ramoni
Franca Podo
Publication date
01-04-2012
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2012
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3151

Other articles of this Issue 2/2012

Breast Cancer Research 2/2012 Go to the issue

Research article

Occurrence of breast cancer subtypes in adolescent and young adult women

Research article

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients

Research article

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Research article

Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study

Research article

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study

Letter

Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits